cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Gt Biopharma Inc
5 own
5 watching
Current Price
$3.07
$0.38
(14.2%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
10.34M
52-Week High
52-Week High
10.66000
52-Week Low
52-Week Low
1.92000
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization10.34M
icon52-Week High10.66000
icon52-Week Low1.92000
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio--
What does the Gt Biopharma Inc do?
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. Its TriKE platform generates therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer (NK) cells. The Company is also using its TriKE platform to develop therapeutics useful for the treatment of infectious disease such as for the treatment of patients infected by the human immunodeficiency virus (HIV). Its GTB-3550 is the first-generation TriKE product candidate which was a single-chain, tri-specific recombinant fusion protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15, all connected by small peptide linkers.
Read More
How much money does Gt Biopharma Inc make?
News & Events about Gt Biopharma Inc.
Globe Newswire
1 year ago
BRISBANE, CALIFORNIA, May 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the Company) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Companys proprietary natural killer (NK) cell engager, TriKE platform, has named Charles J. ...
Globe Newswire
1 year ago
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE platform, today announced that Dr. Jeffrey ...
Globe Newswire
1 year ago
BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the Company or GTB) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE platform, issued an open ...
Globe Newswire
1 year ago
BRISBANE, CALIFORNIA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the Company or GTB) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE platform, today announced ...
Globe Newswire
2years ago
Presentation shows the therapeutic potential of combining iPSC-derived CAR NK cells and NK cell engagers to overcome the clinical heterogeneity of AML BRISBANE, CALIFORNIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) today announced the presentation of new preclinical data at...
Frequently Asked Questions
Frequently Asked Questions
What is Gt Biopharma Inc share price today?
plus_minus_icon
Can Indians buy Gt Biopharma Inc shares?
plus_minus_icon
How can I buy Gt Biopharma Inc shares from India?
plus_minus_icon
Can Fractional shares of Gt Biopharma Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Gt Biopharma Inc stocks?
plus_minus_icon
What is today’s traded volume of Gt Biopharma Inc?
plus_minus_icon
What is today’s market capitalisation of Gt Biopharma Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Gt Biopharma Inc?
plus_minus_icon
What percentage is Gt Biopharma Inc down from its 52-Week High?
plus_minus_icon
What percentage is Gt Biopharma Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$3.07
$0.38
(14.2%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00